<DOC>
	<DOCNO>NCT00930982</DOCNO>
	<brief_summary>The purpose study find bacterial load airway reduce inhalation ciprofloxacin 28 day .</brief_summary>
	<brief_title>Evaluation Cipro Inhale Patients With Non-cystic Fibrosis Bronchiectasis</brief_title>
	<detailed_description>Safety issue address AE section . There standardise unanimously accept definition exacerbation COPD ; 4 definition widely use : ( 1 ) use combination 3 cardinal symptom : increase dyspnea , sputum volume , sputum purulence ; ( 2 ) look presence follow pattern symptom &gt; =2 consecutive day : either 2 3 major symptom ( increase dyspnoea , sputum volume sputum purulence ) ; 1 major symptom together 1 minor symptom ( increase nasal discharge , wheeze , sore throat , cough fever ) ; ( 3 ) sustain worsen patient 's condition , stable state beyond normal day-to-day variation , acute onset necessitates change regular medication patient underlie COPD ; ( 4 ) complex respiratory event ( i.e . cough , wheeze , dyspnoea sputum production ) last &gt; =3 day .</detailed_description>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Patients proven document diagnosis noncystic fibrosis idiopathic post pneumonic bronchiectasis Stable pulmonary status stable regimen standard treatment least past 30 day Forced Expiratory Volume 1 &lt; 35 % &gt; 80 % Allergic bronchopulmonary aspergillosis Immunodeficiency disease require immunoglobulin replacement Inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Ciprofloxacin</keyword>
	<keyword>Airway infection</keyword>
	<keyword>Bronchiectasis</keyword>
</DOC>